Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
|Articles|June 22, 2012
Nutritional and OTC Supplements in Schizophrenia: What Role? (Video 2:53 minutes)
Author(s)Peter F. Buckley, MD
Listen
0:00 / 0:00
Key Takeaways
- ”).
Here: nutritional supplements and over-the counter medications in schizophrenia management.
Advertisement
As part of his webinar presentation "What's New in Schizophrenia," Dr. Peter Buckley answers this single question here:
"What role do nutritional supplements (eg, fish oil and alpha lipoic acid) and over-the-counter medications (such as NSAIDs and aspirin) play in the management of schizophrenia?”
Advertisement
Related to this article
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
3
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
4
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
5